CN105037321A - Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof - Google Patents

Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof Download PDF

Info

Publication number
CN105037321A
CN105037321A CN201510353599.1A CN201510353599A CN105037321A CN 105037321 A CN105037321 A CN 105037321A CN 201510353599 A CN201510353599 A CN 201510353599A CN 105037321 A CN105037321 A CN 105037321A
Authority
CN
China
Prior art keywords
compound
ampk
activating agents
xanthate
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510353599.1A
Other languages
Chinese (zh)
Inventor
邓润卿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foshan Saiweisi Pharmaceutical Technology Co Ltd
Original Assignee
Foshan Saiweisi Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foshan Saiweisi Pharmaceutical Technology Co Ltd filed Critical Foshan Saiweisi Pharmaceutical Technology Co Ltd
Priority to CN201510353599.1A priority Critical patent/CN105037321A/en
Publication of CN105037321A publication Critical patent/CN105037321A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of medicines related to type 2 diabetes mellitus, in particular to xanthate AMPK activating agents comprising hexamethylbenzene ring structures, preparation methods for the xanthate AMPK activating agents, and application of the xanthic acid AMPK activating agents to preparation of medicine for treating type 2 diabetes mellitus. The general formula of the xanthic acid AMPK activating agents is as shown in the description, wherein R is selected from H or alkyls of C1-C3.

Description

Containing AMPK activator, the Preparation method and use of the xanthate class of hexamethyl phenyl ring
Technical field
The present invention relates to the pharmaceutical field of diabetes B treatment.More particularly, the present invention relates to xanthate class AMPK activator, its preparation method of the medicative class of diabetes B tool containing hexamethyl-benzene ring structure, and the purposes in pharmacy.
Background technology
Diabetes are the lysis caused by multi-pathogenesis, have influence on the population in the whole world 6%.Expect 2025, number of patients can double again and reach 300,000,000.The most important clinical pathologic characteristic of diabetes is that plasma glucose (blood sugar) concentration increases.It is the major cause leading diabetogenic various clinical symptom that blood sugar concentration increases.Unsteered hyperglycemia causes many diabetic complications, as increased capillary blood vessel and macrovascular diseases risk, comprises ephrosis, neuropathy, retinopathy, hypertension, cerebral ischemia and coronary heart disease etc.Therefore, the key that blood sugar is treatment and prevent diabetes and complication thereof is reduced.
The protein kinase (AMPK) that AMP (adenylic acid) activates participates in multiple metabolic process as a kind of important protein kinase.AMPK plays master switch effect in the balance of adjuster body energy metabolism.In muscle and liver, the activation of AMPK enhances the picked-up of glucose, fatty acid oxidation and insulin sensitivity, and decreases the generation of glucose, cholesterol and triglyceride level.Therefore, AMPK and signal path thereof are diabetes B active drug action target spots.In fact, the biguanides of widespread use clinically at present, controlling as N1,N1-Dimethylbiguanide, phenformin and buformin is exactly AMPK activator.Wherein N1,N1-Dimethylbiguanide is a current most widely used line antidiabetic medicine clinically, be not only first-selected Remedies for diabetes and also on euglycemia without impact.This shows that AMPK is the keying action target spot of type ii diabetes pharmacological agent.But a severe side effect of these widely used biguanides AMPK activator clinically to cause lactic acidosis at present.Lactic acidosis is the metabolism class disease that a class is serious, once occur threat to life.Just because of causing lactic acidosis, the biguanides AMPK activator such as phenformin are terminated clinical application in states such as America and Europes.Although N1,N1-Dimethylbiguanide causes the probability of lactic acidosis, comparatively phenformin is low, but in oral antidiabetic drug, it causes serious toxic side effects and causes dead clinical report number maximum, therefore, research and develop novel, non-biguanides AMPK activator to have and important clinical meaning as the medicine of diabetes.
The invention discloses the xanthate class AMPK activator of a class containing hexamethyl-benzene ring structure, these compounds can be used for the medicine preparing treatment diabetes B.
Summary of the invention
An object of the present invention is to provide a kind of AMPK agonist with the excellent activity of general formula I.
Another object of the present invention is to provide the method that preparation has the compound of general formula I.
The compound that another object of the present invention is to provide containing general formula I is treating the application in diabetes B as effective constituent.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula I has following structural formula:
Wherein, R is selected from H, C 1-C 3alkyl.
The compound of preferred formula I has following structure,
Compound of Formula I of the present invention is synthesized by following route:
Compound II per reacts with compound III under Louis acid catalysis, obtains compound IV; Compound IV is through BX 3process the methyl sloughed on methoxyl group, obtain VI; Compound VI by first in the presence of a base with CS 2reaction, obtains corresponding xanthogenate, the latter again with after the compound VI I that adds there is substitution reaction, obtain Compound I; Wherein, the definition of X=Br or Cl, R as previously mentioned.
Compound of Formula I of the present invention has AMPK activation, can be used as effective constituent for the preparation of diabetes B medicine.The activity of compound of Formula I of the present invention is verified by receptor binding assays.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-1000mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
the synthesis of embodiment 1 Compound I-1
A. the synthesis of compound IV-1
Compound II per (1.48g, 10mmol) and compound III-1 (1.57g, 10mmol) are dissolved in the CH of 20mL drying 2cl 2in, stirred at ambient temperature, adds anhydrous AlCl 3(1.33g, 10mmol), then reaction mixture at room temperature stirs and spends the night, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use 1% dilute hydrochloric acid and salt water washing successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white solid.ESI-MS,m/z＝269([M+H] +)。
B. the synthesis of compound V-1
Compound IV-1 (1.61g, 6mmol) is dissolved in the CH of 15mL drying 2cl 2in, be cooled to-50 DEG C under nitrogen protection, stir, slowly drip the BCl of 1.0M with syringe 3the CH of (10mL, 10mmol) 2cl 2solution, after dropwising, reaction mixture is warmed up to room temperature gradually, and at room temperature stirs 1 hour, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound V-1, white solid.ESI-MS,m/z＝255([M+H] +)。
The synthesis of C.VI-1
Compound V-1 (1.02g, 4mmol) be dissolved in 10mLTHF, stirred at ambient temperature, add NaOH (0.40g, 10mmol), stirred at ambient temperature 30 minutes, then add (R)-propylene oxide (0.29g, 5mmol), gained reaction mixture then temperature rising reflux 12 hours, TLC shows reaction to be completed.Reaction mixture pours in 100mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-1, white solid.ESI-MS,m/z＝313([M+H] +)。
D. the synthesis of Compound I-1
Compound VI-1 (0.62g, 2mmol) is dissolved in the THF of 10mL drying, and stirred at ambient temperature adds 60%NaH (0.40g, 10mmol), continues stirring 30 minutes, then adds dry CS 2(0.23g, 3mmol), continue stirring 30 minutes, finally add compound VI I-1 (0.40g, 3mmol), reaction mixture at room temperature stirs 5 hours, and TLC follows the tracks of and finds that reaction completes.Reaction mixture pours in 100mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound I-1, white solid.ESI-MS,m/z＝485([M+H] +)。
the synthesis of embodiment 2 Compound I-2
A. the synthesis of compound IV-2
Compound II per (1.48g, 10mmol) and compound III-2 (1.70g, 10mmol) are dissolved in the CH of 20mL drying 2cl 2in, stirred at ambient temperature, adds anhydrous AlCl 3(1.33g, 10mmol), then reaction mixture at room temperature stirs and spends the night, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use 1% dilute hydrochloric acid and salt water washing successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-2, white solid.ESI-MS,m/z＝283([M+H] +)。
B. the synthesis of compound V-2
Compound IV-2 (1.69g, 6mmol) is dissolved in the CH of 15mL drying 2cl 2in, be cooled to-50 DEG C under nitrogen protection, stir, slowly drip the BCl of 1.0M with syringe 3the CH of (10mL, 10mmol) 2cl 2solution, after dropwising, reaction mixture is warmed up to room temperature gradually, and at room temperature stirs 1 hour, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound V-2, white-yellowish solid.ESI-MS,m/z＝269([M+H] +)。
The synthesis of C.VI-2
Compound V-2 (1.07g, 4mmol) be dissolved in 10mLTHF, stirred at ambient temperature, add NaOH (0.40g, 10mmol), stirred at ambient temperature 30 minutes, then add (R)-propylene oxide (0.29g, 5mmol), gained reaction mixture then temperature rising reflux 12 hours, TLC shows reaction to be completed.Reaction mixture pours in 100mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-2, white solid.ESI-MS,m/z＝327([M+H] +)。
D. the synthesis of Compound I-2
Compound VI-2 (0.65g, 2mmol) is dissolved in the THF of 10mL drying, and stirred at ambient temperature adds 60%NaH (0.40g, 10mmol), continues stirring 30 minutes, then adds dry CS 2(0.23g, 3mmol), continue stirring 30 minutes, finally add compound VI I-1 (0.40g, 3mmol), reaction mixture at room temperature stirs 5 hours, and TLC follows the tracks of and finds that reaction completes.Reaction mixture pours in 100mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound I-2, white solid.ESI-MS,m/z＝499([M+H] +)。
embodiment 3-9
With reference to embodiment 1 operation steps, synthesize compound listed in Table.
embodiment 5 Compound ira vitro is to the activation of AMPK
To recombinate AMPK enzyme reactivating with LKBl in vitro before enzyme assay expression in escherichia coli people.Use two kinds of technology for detection AMPK enzymic activitys based on fluorescence (α-screening and Delfia) and (comprise 25mMTris/HCl damping fluid, pH7.5, Hepes damping fluid containing 100 μMs of ATP/50mM respectively at microwell plate, 25mMTris/HCl damping fluid, pH7.4, containing 125 μMs of ATP) on synthesis skin substrate (AMARAASAAALARRR, i.e. " AMARAA " skin) and serial dilution activator existence under carry out.By adding AMPK (50-100ng) initiation reaction.After mixing, plank is at room temperature hatched 30 minutes.Enzymic activity is detected to measure the phosphoric acid amount of mixing in AMARAA by using the antibody of anti-phosphorylate serine.Activity represents with the percentage (%) contrasting (Basal activity is expressed as 100).
Test result sees the following form.
Compound α-screening Delfia
Compound I-1 135 171
Compound I-2 192 194
Compound I-3 187 235
Compound I-4 129 177
As can be seen from upper table result, compound of the present invention has very strong activation to AMPK, can as preparation treatment diabetes B medicine.

Claims (4)

1. there is the compound of general formula I,
Wherein, R is selected from H, C 1-C 3alkyl.
2. the compound of Formula I that defines of claim 1, is selected from following compounds,
3. synthesize arbitrary the defined method belonging to the compound of general formula (I) of claim 1-2:
Compound II per reacts with compound III under Louis acid catalysis, obtains compound IV; Compound IV is through BX 3process the methyl sloughed on methoxyl group, obtain VI; Compound VI by first in the presence of a base with CS 2reaction, obtains corresponding xanthogenate, the latter again with after the compound VI I that adds there is substitution reaction, obtain Compound I; Wherein, the definition of X=Br or Cl, R as arbitrary in claim 1-2 as described in.
4. the compound of Formula I that one of claim 1-2 defines is preparing the application in treatment diabetes B medicine.
CN201510353599.1A 2015-06-23 2015-06-23 Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof Pending CN105037321A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510353599.1A CN105037321A (en) 2015-06-23 2015-06-23 Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510353599.1A CN105037321A (en) 2015-06-23 2015-06-23 Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof

Publications (1)

Publication Number Publication Date
CN105037321A true CN105037321A (en) 2015-11-11

Family

ID=54444356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510353599.1A Pending CN105037321A (en) 2015-06-23 2015-06-23 Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof

Country Status (1)

Country Link
CN (1) CN105037321A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5330696A (en) * 1976-06-23 1978-03-23 Mitsui Toatsu Chem Inc Preparation of improved highly elastic urethane forms
CN101998853A (en) * 2008-04-11 2011-03-30 默克专利有限公司 Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
CN104395319A (en) * 2012-06-29 2015-03-04 普克塞尔公司 Thienopyridone derivatives useful as activators of ampk

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5330696A (en) * 1976-06-23 1978-03-23 Mitsui Toatsu Chem Inc Preparation of improved highly elastic urethane forms
CN101998853A (en) * 2008-04-11 2011-03-30 默克专利有限公司 Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
CN104395319A (en) * 2012-06-29 2015-03-04 普克塞尔公司 Thienopyridone derivatives useful as activators of ampk

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAO PANG ET AL.: "Small Molecule Antagonizes Autoinhibition and Activates AMP-activated Protein Kinase in Cells", 《THE JOURNAL OF BIOLOGOCAL CHEMISTRY》 *

Similar Documents

Publication Publication Date Title
US20100234433A1 (en) Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
US20190040029A1 (en) A type of aryl benzofuran amidated derivative and medical use thereof
CN107162921A (en) The new Phenoxiacetic acid derivatives of one class, its preparation method and its purposes as medicine
CN105037321A (en) Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof
CN105037322A (en) Xanthate compounds containing hexamethylbenzene ring and alkoxyl benzene structures, as well as preparation methods and application thereof
CN104945431B (en) A kind of preparation method of the schiff bases vanadyl complex crystal for having biological activity
CN104892569A (en) Terminal-substituted nitrobenzene hexamethylbenzene xanthate compound, preparation method and application
CN104945370A (en) Xanthate compound containing halothiophene and nitrobenzene hexamethylbenzene structure, preparation method and application
CN105001194A (en) Xanthate compound containing aminothiophene and hexamethylbenzene structures, and preparation method and application thereof
CN104910129A (en) Xanthate compounds containing hexamethyl benzene ring and halogeno-benzene, and preparation method and application thereof
CN104945369A (en) Xanthic acid ester compound containing hexamethyl benzene ring and nitrobenzene structures and preparation method and application thereof
CN104945371A (en) Xanthate ester compound containing nitrile thiophene and with hexamethylbenzene structure and preparation method and application thereof
CN104910130A (en) Xanthate compound containing hexamethylbenzene ring and aminobenzene structures as well as preparation method and application thereof
CN104945372A (en) Dinitrosalicylic xanthate ester compound with hexamethylbenzene structure and preparation method and application thereof
CN104892568A (en) Xanthate ester compound containing haxamethyl benzene ring and nitrile group benzene structure and preparation method and application of xanthate ester compound
CN112679409B (en) 4-indole-substituted thiosemicarbazide derivative and preparation method and application thereof
CN115385819A (en) Rosmarinic acid bioelectronic isostere and preparation method and application thereof
CN104926757A (en) Diacyl benzylamine AMPK activator containing alcoxyl phenyl group, and preparation method and purpose of diacyl benzylamine AMPK activator
CN104926756A (en) Di-acyl benzylamine compound with cyano benzene, method for manufacturing di-acyl benzylamine compound and application thereof
CN104926755A (en) Nitrobenzene di-acyl benzylamine AMPK (adenosine monophosphate activated protein kinase) activator, method for manufacturing same and application of nitrobenzene di-acyl benzylamine AMPK activator
CN105001181A (en) Bisacyl benzylamine AMPK activator, and preparation method and application thereof
CN105237595A (en) N2-glycosyl-substituted 1,2,3-triazole compound and synthesis method and application thereof
CN105037296A (en) AMPK activator containing halogenated-benzene bisamides benzylamine structures, and preparation method and application thereof
WO2004101493A1 (en) Acid addition salt of carbasugar amine derivative
JP7050005B2 (en) Crystal transformation of N- (4,5-bismethanesulfonyl-2-methylbenzoyl) guanidine hydrochloride and N- (4,5-bismethanesulfonyl-2-methylbenzoyl) guanidine salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151111

RJ01 Rejection of invention patent application after publication